《新股消息》先瑞達醫療(06669.HK)今日起招股 入場費24,039元
內地創新醫療器械企業先瑞達醫療(06669.HK)公布招股詳情,計劃發行6,863.3萬股股份,當中10%在港公開發售,招股價介乎22.2元至23.8元,每手1,000股,入場費24,039.83元。由今日(12日)至下周二(17日)公開招股,預計將於8月24日上市。摩根士丹利及中金為聯席保薦人。
公司是次上市引入13名基石投資者,合共認購1.05億美元股份。以招股價中位數23元計,公司預計集資淨額為14.74億元,當中32%將被分配予其核心產品;23%將分配予現有產品管線中餘下的24款產品;24%將用於為通過內部研發、合作、合併及收購、授權引進或股權投資等方式擴大產品組合提供資金;7%將用於擴大生產能力及強化製造能力;8%用於營運資金及一般企業用途;6%用於償還貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.